ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 18.75
(3.88%)
TWD 18.75
(3.88%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 570.23 Million TWD | -1.88% |
| 2022 | 581.18 Million TWD | 7.57% |
| 2021 | 540.26 Million TWD | -1.8% |
| 2020 | 550.18 Million TWD | -6.75% |
| 2019 | 590.02 Million TWD | 0.0% |
| 2018 | - TWD | -100.0% |
| 2017 | 1.09 Billion TWD | 42.39% |
| 2016 | 770.87 Million TWD | 0.0% |
| 2015 | - TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| 2010 | - TWD | -100.0% |
| 2009 | 643.99 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 627.69 Million TWD | 55.3% |
| 2024 Q2 | 624.92 Million TWD | 100.0% |
| 2023 Q1 | 578.37 Million TWD | -0.48% |
| 2023 Q3 | 572.72 Million TWD | -0.49% |
| 2023 Q4 | 570.23 Million TWD | -0.44% |
| 2023 Q2 | 575.55 Million TWD | -0.49% |
| 2023 FY | 570.23 Million TWD | -1.88% |
| 2022 Q4 | 581.18 Million TWD | -0.25% |
| 2022 Q2 | 585.11 Million TWD | -0.42% |
| 2022 Q1 | 587.56 Million TWD | 8.76% |
| 2022 FY | 581.18 Million TWD | 7.57% |
| 2022 Q3 | 582.64 Million TWD | -0.42% |
| 2021 Q2 | 545.07 Million TWD | -0.47% |
| 2021 Q4 | 540.26 Million TWD | -0.41% |
| 2021 Q1 | 547.63 Million TWD | -0.46% |
| 2021 FY | 540.26 Million TWD | -1.8% |
| 2021 Q3 | 542.5 Million TWD | -0.47% |
| 2020 Q4 | 550.18 Million TWD | -0.22% |
| 2020 Q2 | 553.67 Million TWD | -11.3% |
| 2020 Q1 | 624.21 Million TWD | 5.8% |
| 2020 FY | 550.18 Million TWD | -6.75% |
| 2020 Q3 | 551.38 Million TWD | -0.41% |
| 2019 Q3 | 772.53 Million TWD | -60.5% |
| 2019 Q4 | 590.02 Million TWD | -23.63% |
| 2019 Q2 | 1.95 Billion TWD | 123.89% |
| 2019 Q1 | 873.5 Million TWD | 0.0% |
| 2019 FY | 590.02 Million TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 FY | - TWD | -100.0% |
| 2018 Q1 | 1.18 Billion TWD | 7.92% |
| 2018 Q2 | - TWD | -100.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2017 Q1 | 731.06 Million TWD | -5.16% |
| 2017 FY | 1.09 Billion TWD | 42.39% |
| 2017 Q4 | 1.09 Billion TWD | -10.62% |
| 2017 Q3 | 1.22 Billion TWD | 1.39% |
| 2017 Q2 | 1.21 Billion TWD | 65.68% |
| 2016 FY | 770.87 Million TWD | 0.0% |
| 2016 Q3 | 795.3 Million TWD | 217.93% |
| 2016 Q2 | 250.14 Million TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 Q4 | 770.87 Million TWD | -3.07% |
| 2015 Q1 | - TWD | 0.0% |
| 2015 FY | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2011 Q3 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| 2010 FY | - TWD | -100.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 643.99 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | -318.181% |
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | -155.74% |
| Maywufa Company Ltd. | 438.97 Million TWD | -29.9% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 94.01% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -157858.726% |
| YungShin Global Holding Corporation | 241.99 Million TWD | -135.637% |
| PhytoHealth Corporation | 17.46 Million TWD | -3165.928% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | 32.559% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | 72.019% |
| PharmaEssentia Corporation | 954.99 Million TWD | 40.29% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 83.647% |